Clonidine
Clonidine
- In our pharmacy, you can buy clonidine without a prescription, with delivery in 5–14 days throughout Australia. Discreet and anonymous packaging.
- Clonidine is used for hypertension, ADHD (extended‑release formulations), severe cancer pain (epidural), and for managing alcohol/opioid withdrawal; it is a centrally acting alpha‑2 adrenergic agonist (with imidazoline receptor activity) that reduces sympathetic outflow.
- The usual dose for adults with hypertension is 0.1 mg twice daily, titrating by 0.1 mg every 1–2 weeks (maximum ~2.4 mg/day); for ADHD ER tabs start 0.1 mg at night and increase by 0.1 mg/week up to ~0.4 mg/day; transdermal patches deliver 0.1–0.3 mg/24 h; injectable concentrations are typically 100–500 mcg/mL for clinical use.
- Administration forms include oral tablets (immediate and extended‑release), transdermal patches, injection (IV/epidural) and, in select markets, ophthalmic drops.
- Onset of action: oral tablets usually begin to work within 30–60 minutes; transdermal patches require several hours with therapeutic effect by ~12–24 hours; injectable/epidural effects occur within minutes.
- Duration of action: immediate‑release oral effects commonly last ~6–12 hours; extended‑release tablets and transdermal patches provide up to 24 hours of effect (plasma half‑life ~12–16 hours).
- Alcohol warning: avoid alcohol while taking clonidine — it increases drowsiness, sedation and the risk of dizziness, respiratory depression and hypotension.
- The most common side effect is dry mouth.
- Would you like to try clonidine without a prescription?
Basic Clonidine Information
- INN (International Nonproprietary Name): Clonidine.
- Brand Names Available In Australia: Catapres (tablets and patches), Catapres‑TTS transdermal patches, Kapvay (extended‑release), with generics such as APO‑Clonidine appearing in other markets; injectable Duraclon is used in hospitals.
- ATC Code: C02AC01 (Antihypertensives, Imidazoline Derivatives).
- Forms & Dosages: Tablets 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg; Kapvay ER 0.1 mg and 0.2 mg; Transdermal patches 0.1 mg, 0.2 mg, 0.3 mg per 24 h; Injections 100 mcg/mL and 500 mcg/mL.
- Manufacturers In Australia: Global suppliers active in markets including Pfizer, Boehringer Ingelheim, Sandoz/Novartis, Mylan and Teva; local supply commonly relies on Australian wholesalers importing branded or generic stock.
- Registration Status In Australia: TGA S4 prescription medicine; pregnancy category B3.
- OTC / Rx Classification: Prescription only (S4) in Australia and Rx in major markets.
Latest Research Highlights (Australian + International, 2022–2025)
Are you wondering what the newest studies say about clonidine?
Recent Australian and international evidence from 2022–2025 reaffirm clonidine as a well‑established central alpha‑2 agonist with consistent antihypertensive efficacy.
Systematic reviews up to 2024–25 show clonidine keeps lowering blood pressure reliably when used as add‑on therapy and retains a clear pharmacological profile.
Transdermal formulations consistently appear in population studies as improving adherence in older adults and reducing peak–trough variability compared with oral dosing.
Paediatric trials of extended‑release clonidine (Kapvay) report modest benefits for sleep onset and impulsivity in ADHD when combined with behavioural therapy rather than as a stimulant replacement.
Perioperative and epidural uses remain supported by trials showing opioid‑sparing analgesia in several procedural and palliative contexts.
Research syntheses highlight predictable adverse effects — sedation, dry mouth and mild hypotension — and emphasise the clinically important risk of rebound hypertension on abrupt withdrawal.
Australian pharmacovigilance via TGA adverse‑event reports continues to track patch site reactions and bradycardia signals, particularly in elderly patients on multiple medicines.
Efficacy Outcomes — Summary Table
| Outcome | Typical Change | Notes |
|---|---|---|
| Hypertension (BP Reduction) | Systolic/Diastolic reduction consistent with add‑on therapy | Used where ACE inhibitors or beta‑blockers are unsuitable |
| ADHD Symptom Change (Kapvay ER) | Modest improvement in sleep and impulsivity | Best used with behavioural therapy; less effect than stimulants |
| Withdrawal Symptom Scores (Opioid/Alcohol) | Reduction in autonomic and agitation scores | Symptomatic relief; does not replace opioid agonist therapy |
Safety Events — Summary Table
| Event | Frequency/Signal | Clinical Action |
|---|---|---|
| Sedation / Drowsiness | Common | Advise caution with driving; dose timing often at night |
| Dry Mouth | Common | Symptomatic care; oral hygiene advice |
| Patch Site Reactions | Reported (TGA) | Rotate sites; topical measures or switch to oral if persistent |
| Bradycardia / Hypotension | Noted in elderly polypharmacy cases | Monitor pulse and BP; review interacting drugs |
Clinical Effectiveness In Australia (PBS/TGA Data And Outcomes)
How does clonidine perform in everyday Australian practice?
Clinical outcomes in Australia broadly mirror international efficacy but are shaped by PBS prescribing rules, rural access and primary‑care follow‑up patterns.
For hypertension, clonidine produces consistent systolic and diastolic reductions when used as add‑on therapy in patients who cannot tolerate first‑line agents.
PBS dispensing data show lower overall use compared with ACE inhibitors or beta‑blockers, but clonidine maintains a steady niche when other agents are unsuitable.
TGA monitoring flags expected central nervous system effects such as drowsiness and hypotension, together with patch dermatitis reports.
Kapvay ER is available in Australia and is used by paediatricians selectively for ADHD where stimulants are contra‑indicated or cause sleep disruption.
Paediatric outcomes emphasise improved night‑time settling and reduced impulsivity, but smaller effects on core ADHD symptoms than stimulant therapy.
Epidural and injectable clonidine remain evidence‑backed options in palliative and procedural pain for opioid‑sparing effects in hospital settings.
Quick Table: PBS Dispensing, Uses And TGA Reports
| Measure | Australian Context | Notes |
|---|---|---|
| PBS Dispensing Volume (Relative) | Lower than ACE inhibitors and beta‑blockers | Steady niche use for specific indications |
| Common Hospital Uses | Epidural analgesia, palliative injections, perioperative adjunct | Hospital‑only injectable formulations |
| TGA Reported Adverse Events | Patch dermatitis, bradycardia in elderly polypharmacy | Monitor and report via TGA pharmacovigilance |
- Clinical Pearl: Review concurrent antihypertensives and heart rate before starting clonidine in older patients.
- Clinical Pearl: Kapvay ER is most useful for ADHD when sleep disturbance is a primary concern.
- Clinical Pearl: Use epidural clonidine under specialist supervision for opioid‑sparing analgesia in cancer pain.
Indications And Expanded Uses
What can clonidine be used for in Australia and beyond?
- Approved (TGA/Label)
- Hypertension and anaesthetic/procedural uses (IV/epidural); Kapvay ER is registered internationally for paediatric ADHD and is available in Australia.
- Common Off‑Label Uses
- Symptomatic management of opioid and alcohol withdrawal, adjunctive migraine therapy in refractory cases, and short‑term sleep support in ADHD when clinically indicated.
- Specialist/Hospital Uses
- Epidural clonidine for severe cancer pain and perioperative analgesia as an opioid‑sparing adjunct under specialist control.
- Evidence Strength: Hypertension — licensed and robust evidence.
- Evidence Strength: ADHD — ER product shows modest benefit for sleep/impulsivity; used selectively.
- Evidence Strength: Withdrawal and migraine — smaller trials and pragmatic clinical use guide practice.
Composition And Brand Landscape
Which brands and strengths are commonly seen in Australia?
The active ingredient is clonidine hydrochloride (INN: Clonidine).
Catapres appears in tablets and Catapres‑TTS patches in strengths that include 100 mcg and 150 mcg tablets and transdermal patches delivering 0.1–0.3 mg per 24 hours.
Kapvay ER is supplied as extended‑release 0.1 mg and 0.2 mg tablets for paediatric ADHD.
Hospital injectable Duraclon formulations (100 mcg/mL and 500 mcg/mL) are used for epidural or IV administration.
Brands, Forms And Likely PBS Availability
| Brand | Form | Common Dosages | PBS Notes |
|---|---|---|---|
| Catapres | Tablets, Patches | 100 mcg, 150 mcg; Patches 0.1–0.3 mg/24 h | Some formulations may be PBS‑listed depending on indication and pack |
| Kapvay | Extended‑Release Tablets | 0.1 mg, 0.2 mg | Available in Australia; PBS subsidy depends on criteria |
| Generic (APO‑Clonidine etc.) | Tablets | 0.1 mg, 0.15 mg, 0.2 mg | Generics often supplied via wholesalers; check local stock |
- Community pharmacies generally stock tablet formulations, while patches and ER tablets may require special order or hospital supply.
- Major suppliers include Pfizer, Boehringer Ingelheim, Sandoz/Novartis, Mylan and Teva; local availability can vary.
Contraindications And Special Precautions
Who should avoid clonidine or use it with extra care?
- Absolute Contraindications: Known hypersensitivity to clonidine or excipients; severe bradyarrhythmia or advanced AV block unless the patient has a pacemaker.
- Relative Concerns: Recent myocardial infarction — use with specialist monitoring; depression; severe orthostatic hypotension.
| Risk Group | Monitoring / Action Required |
|---|---|
| Elderly | Start low (eg 0.05 mg BID), monitor BP and pulse, review interacting drugs to reduce fall risk. |
| Renal Impairment | Reduce dose; observe for increased CNS depression and hypotension. |
| Hepatic Impairment | Use cautiously; titrate slowly with clinical monitoring. |
| Pregnancy / Breastfeeding | TGA pregnancy category B3; weigh benefits versus risks and consult specialist. |
| Indigenous / Remote‑Living Patients | Assess comorbidities (CVD, renal disease), ensure culturally safe counselling and arrange follow‑up given access challenges. |
Dosage Guidelines
What dosing patterns should pharmacists and prescribers follow in Australia?
Hypertension (Adults): start around 0.1 mg twice daily and titrate by 0.1 mg every 1–2 weeks as tolerated.
Maximum reported doses are up to 2.4 mg/day under specialist supervision; such doses require careful monitoring.
ADHD (Paediatric, Kapvay ER): start 0.1 mg at night, increase by 0.1 mg per week per response and tolerability, with common total doses up to 0.4 mg/day divided as needed.
Withdrawal (Opioid/Alcohol): symptomatic dosing often 0.1–0.2 mg every 4–6 hours, titrated to effect while avoiding excessive cumulative sedation.
Epidural/Injectable (Palliative): hospital titration examples include continuous infusions around 30 mcg/hr, titrated by specialist teams.
| Indication | Typical Starting Dose | Adjustment Notes |
|---|---|---|
| Hypertension (Adult Oral) | 0.1 mg twice daily | Titrate 0.1 mg every 1–2 weeks; monitor BP |
| ADHD (Kapvay ER, Paediatric) | 0.1 mg at night | Increase 0.1 mg weekly to effect; watch sedation |
| Withdrawal Symptom Control | 0.1–0.2 mg every 4–6 hrs PRN | Short‑term use preferred; monitor for oversedation |
- Tapering: Avoid abrupt cessation to prevent rebound hypertension — reduce dose gradually under supervision.
- Missed Dose: Take as soon as remembered unless near the next dose; do not double dose.
Interactions Overview
Which medicines and substances commonly interact with clonidine?
Major interaction themes include additive hypotension and bradycardia when clonidine is combined with ACE inhibitors, beta‑blockers or diuretics.
CNS depressants such as alcohol, opioids, benzodiazepines, antipsychotics and sedating antihistamines potentiate sedation and respiratory depression risk.
Tricyclic antidepressants may antagonise clonidine’s antihypertensive effects and complicate withdrawal management.
Pharmacokinetic interactions are limited, but caution is sensible when combining with medicines that alter hepatic metabolism or renal clearance in frail patients.
| Drug Class | Interaction Effect | Monitoring / Action |
|---|---|---|
| ACE Inhibitors / ARBs / Diuretics | Increased hypotension | Monitor BP; consider dose adjustment |
| Beta‑Blockers | Enhanced bradycardia and hypotension | Check pulse regularly; avoid if severe bradycardia |
| Opioids / Alcohol / Benzodiazepines | Increased CNS depression | Avoid combination where possible; counsel on sedation |
| Tricyclic Antidepressants | Reduced antihypertensive effect | Review antidepressant regimen and BP control |
Cultural Perceptions And Patient Habits
What do Australian patients say online and in community practice?
Patients commonly search for brand‑specific terms such as “Clonidine Catapres 0.15mg” and discuss sleep effects, withdrawal uses and patch convenience on forums.
Price sensitivity and PBS subsidy status strongly influence purchasing choices and brand preference.
Pharmacists are trusted sources of advice, and major community chains like Chemist Warehouse, Priceline and TerryWhite Chemmart are frequent patient touchpoints.
Rural and remote patients face less frequent GP follow‑up, limited specialist access and potential patch supply interruptions, so telehealth prescriptions and local dispensing arrangements matter.
Indigenous health services stress culturally safe counselling, shared decision‑making and close follow‑up given higher burdens of cardiovascular and renal disease.
In remote towns a nurse‑led clinic may coordinate repeat prescriptions and teach patch care to reduce missed doses and adverse effects.
Availability And Pricing Patterns
Where can Australians get clonidine and what will it cost?
Clonidine tablets are stocked by major chains and community pharmacies, while transdermal patches and Kapvay ER may require special order or hospital supply.
Online pharmacies and telehealth platforms commonly provide e‑prescriptions for stable patients; verify pack authenticity and TGA‑approved brands when ordering.
Pricing depends on PBS subsidy for the specific formulation and indication; where not PBS‑subsidised, private prices vary with tablets generally cheaper than ER tablets and patches.
Rural patients can face postage and delay costs, so consider arranging repeats or local health service coordination to ensure continuity.
In our online pharmacy, clonidine is available without a prescription, with discreet delivery to Australia in 5–14 days.
| Product Form | Typical Availability | Typical Price Range (Private) |
|---|---|---|
| Clonidine Tablets (0.1–0.3 mg) | Common in community pharmacies | Lower price band compared with ER/patch |
| Kapvay ER (0.1–0.2 mg) | Limited community stock; may require order | Higher price band; PBS subsidy variable |
| Catapres‑TTS Patches (0.1–0.3 mg/24 h) | Available but less widely stocked | Higher price; check availability before prescribing |
Comparable Medicines And Preferences
What are the practical alternatives to clonidine in Australia?
| Comparator | Pros | Cons |
|---|---|---|
| Methyldopa | Central antihypertensive useful in pregnancy | Hepatic side‑effects; less used now |
| Guanfacine | For paediatric ADHD; sometimes less sedating than clonidine | Different side‑effect profile and PBS access considerations |
| Beta‑Blockers / ACE Inhibitors | Well‑established first‑line BP control | May be unsuitable in some comorbidities |
| Atomoxetine / Stimulants | Greater effect on core ADHD symptoms | Stimulants have abuse potential and sleep effects |
- Decision Tip: Choose based on PBS listing, side‑effect profile and comorbidities rather than convenience alone.
- Withdrawal Support: Clonidine treats symptoms, whereas buprenorphine and methadone treat opioid dependence and may be preferred for maintenance therapy.
FAQ
Will clonidine make me sleepy?
Yes, clonidine commonly causes drowsiness, especially when starting treatment or after dose increases.
Avoid driving or heavy machinery until you know how it affects you.
Can I stop clonidine suddenly?
No — abrupt cessation risks rebound hypertension and agitation.
Reduce the dose gradually under medical supervision.
Is clonidine available on the PBS?
Some formulations and indications may be PBS‑listed; check the current PBS schedule or ask your pharmacist for subsidy eligibility.
Can I combine clonidine with alcohol or sedatives?
Combining increases sedation and hypotension risk and should be avoided unless advised and closely monitored by a clinician.
When To Seek Urgent Care
| Sign | Action |
|---|---|
| Severe dizziness or fainting | Seek urgent medical attention |
| Very slow heartbeat or breathlessness | Call emergency services or present to ED |
| Marked rash at patch site with systemic symptoms | Stop patch and seek medical review |
Guidelines For Proper Use (Pharmacist Counselling & PBS/National Advice)
What should pharmacists tell patients starting clonidine?
- Confirm the indication and review the patient’s full medication list for interactions and fall risk.
- Explain sedation risk and advise against driving until tolerant.
- Provide missed‑dose instructions: take as soon as remembered unless close to the next dose; do not double up.
- Emphasise gradual tapering and the dangers of abrupt cessation.
Storage And Patch Care:
- Tablets: store at 15–30°C and protect from moisture.
- Patches: keep sealed until use, store flat away from heat and direct sun, rotate sites and fold patch onto itself before disposal.
PBS And National Advice:
Check PBS eligibility for subsidised supply and consult TGA safety advisories for updates on patch dermatitis or bradycardia signals.
For remote patients, arrange longer‑run scripts or coordinate with local health services to ensure continuity of care.
Pharmacist Counselling Checklist
- Confirm indication, dose and duration.
- Review interactions (antihypertensives, CNS depressants).
- Advise on driving, alcohol avoidance and patch technique.
- Provide written handout on tapering and when to seek urgent care.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Geelong | Victoria | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Alice Springs | Northern Territory | 5-9 days |